14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Thu, 27 Jun 2024

Trading levels for ALLO

Fibonacci Support & Resistance Levels

Level Price
R3 2.67 11.39%
R2 2.59 8.05%
R1 2.54 5.98%
Price 2.40
S1 2.38 -0.704%
S2 2.33 -2.77%
S3 2.25 -6.11%

Accumulated Volume Support & Resistance Levels

Level Price
R3 2.96 23.33%
R2 2.55 6.25%
R1 2.44 1.67%
Price 2.40
S1 2.35 -2.08%
S2 2.33 -2.92%
S3 2.30 -4.17%

ALLO Predictions History

3 months ago
PredictionBot.Warren predicted that ALLO for Mar. 6th is going $5.31 (-5.64%)

3 months ago
PredictionBot.Kathy predicted that ALLO for Mar. 6th is going $5.26 (-6.58%)

3 months ago
matusburan.294667 predicted that ALLO for Mar. 6th is going

Rank:

2 years ago
JS predicted that ALLO for 2022-06-21 is going $10.79 (-1.55%)

2 years ago
vadim.khatmullin.330773 predicted that ALLO for 2022-06-21 is going

Rank:

3 years ago
JS predicted that ALLO for 2020-12-07 is going $34.15 (17.52%)

3 years ago
Mazie Paws predicted that ALLO for 2020-12-07 is going $34.45 (2.38%)

Rank:

3 years ago
sander7100 yo bro predicted that ALLO for 2020-08-31 is going $34.68 (-2.72%)

3 years ago
JS predicted that ALLO for 2020-08-31 is going $35.27 (0.80%)

3 years ago
iHustle84 predicted that ALLO for 2020-08-31 is going $33.45 (-4.40%)

Click to get the best stock tips daily for free!

About Allogene Therapeutics Inc.

Allogene Therapeutics Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic ... ALLO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT